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Abstract 
Growth hormone (GH) regulates somatic growth, substrate metabolism and body 
composition. Sex hormones exert profound effect on the secretion and action of GH. 
Estrogens stimulate the secretion of GH, but inhibit the action of GH on the liver, an effect 
that occurs when administered orally. Estrogens suppress GH receptor signaling by 
stimulating the expression proteins that inhibit cytokine receptor signaling. This effect of 
estrogens is avoided when physiological doses of estrogens are administered via a non-oral 
route. Estrogen-like compounds, such as selective estrogen receptor modulators, possess dual 
properties of inhibiting the secretion as well as the action of GH. In contrast, androgens 
stimulate GH secretion, driving IGF-1 production. In the periphery, androgens enhance the 
action of GH. The differential effects of estrogens and androgens influence the dose of GH 
replacement in patients with hypopituitarism on concomitant treatment with sex steroids. 
Where possible, a non-oral route of estrogen replacement is recommended for optimising 
cost-benefit of GH replacement in women with GH deficiency. Adequate androgen 
replacement in conjunction with GH replacement is required to achieve the full anabolic 
effect in men with hypopituitarism. 
 
 Keywords: estrogen, tamoxifen, testosterone, GH action, anabolism, liver 
 
1. Introduction 
Growth hormone (GH) regulates substrate metabolism, body composition, physical 
performance and general wellbeing in adult life. The importance of the physiological action 
of GH is exemplified by the consequences of GH deficiency (GHD), characterized by a 
reduction in lean body mass and an increase in fat mass [1]. These body composition 
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abnormalities, including reduced muscle mass, are reversed by GH replacement therapy [2-6]. 
Muscle strength [7-9] improves with GH replacement [10, 11].  
   
In addition to reduced muscle strength, aerobic exercise capacity, measured as VO2max, is 
impaired in adults who are GH-deficient by about 20% [7]. A meta-analysis of 11 randomized 
placebo controlled studies has reported that GH replacement improves VO2max in people 
who are GH deficient [12]. The improvements occur through several mechanisms, which 
include effects on cardiorespiratory function, red cell and blood volume. Recent evidence 
indicates that GH enhances anaerobic exercise capacity by promoting anaerobic metabolism. 
In patients with GHD, anaerobic exercise capacity is reduced [13]. A study in recreational 
athletes revealed that GH stimulates sprint capacity, a performance measure dependent on the 
anaerobic energy system [14]. Therefore, many aspects of metabolism, body composition, 
physical function and wellbeing are affected in patients with GHD and improved by GH 
replacement. 
   
During GH replacement, many factors influence the response to, and effectiveness of, 
treatment. The response to GH therapy is influenced by the actions of several hormones. Sex 
steroids require special consideration, as they are one of the most influential regulators of GH 
secretion and peripheral action. Here, we will discuss how sex steroids interact with the 
GH/IGF-1 system and the clinical implications for GHD patient management.    
 
2. Estrogens and GH 
GH is secreted in a pulsatile manner, stimulated by GH-releasing hormone and inhibited by 
somatostatin (SST). Many factors regulate GH secretion.  These include GH releasing peptide 
(GHRP; ghrelin), glucose, free fatty acids, amino acids (arginine), sex steroids, thyroid 
hormones, corticotropin-releasing hormone, adrenergic system, neurotransmitters, 
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neuropeptide Y, leptin, IGF-1, and GH itself [15]. Sex steroids not only influence GH 
secretion directly, but also modulate many factors that regulate GH secretion [16-18].  
 
2.1. Sexual Dimorphism 
Strong evidence indicates that sex steroids modulate GH secretion in men and women. 
Regulation of gender-dimorphic GH secretion patterns is largely SST-dependent [19]. 
Women have higher baseline and mean GH levels than men [20, 21]. This differential pattern 
of GH secretion result in gender-dimorphic expression of several hepatic genes involved in 
glucose and lipid metabolism, energy and protein processing, including the cytochrome p450 
gene [22].  
 
2.2. GH Secretion Regulation by Estrogens 
During the female menstrual cycle, a peri-ovulatory increase occurs in GH secretion. 
Estrogen regulation of GH secretion occurs at the pituitary [23, 24] and hypothalamus [25, 
26]. High levels of estrogen receptors ERα are expressed in the hypothalamus and the 
pituitary. Recent evidence has also revealed expression of ERβ in the somatotroph, with both 
receptor subtypes involved in the regulation of GH gene expression [27, 28]. Furthermore, 
estrogen reduces SST receptor expression, which in turn results in enhancing GH secretion 
[29-31]. Estrogen also enhances ghrelin-induced increase in GH secretion [18, 32]. Therefore, 
estrogens play a major role in the regulation of GH secretion.  
 
2.2. Paracrine Regulation 
Strong evidence has shown that local estrogens, derived from aromatization of testosterone, 
stimulates GH secretion in humans. In human pituitaries, more than 80% of the somatotropes 
co-express aromatase [33]. Aromatase knockout (ArKO) mice or human aromatase gene 
mutation present unique models in understanding the role of estrogen in the regulation of 
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somatotroph function. In ArKO mice, pituitaries are hypoplastic and GH secretion is reduced 
[34]. In men with aromatase deficiency, the GH response to stimulation is substantially 
blunted and is not restored by systemic estradiol replacement [35]. This observation indicates 
that locally produced rather than circulating estrogen stimulates the secretion of GH. There is 
strong evidence that local rather than systemic estrogens drive GH secretion in women. We 
reported that blockade of estrogen action by tamoxifen reduced GH secretion in 
postmenopausal women [36, 37]. As the menopause is an estrogen-deficient state and 
tamoxifen did not change circulating estrogen levels, this finding provides compelling 
evidence that estrogen regulates GH secretion via a paracrine mechanism. Therefore, local 
estrogens derived from aromatization of androgens drives GH secretion in both men and 
women.  
2.3. Endocrine Effect  
The effect of estrogen on GH secretion is dependent on the route of administration. 
Administration of estrogen by the oral route stimulates GH secretion, whereas administration 
by the transdermal route does not [38]. When administered orally, estrogen reduces hepatic 
IGF-1 production as a result of first-pass effect, whereas this does not occur when 
administered transdermally [38]. The fall in IGF-1 after oral estrogen therapy reduces 
negative feedback on GH secretion. Therefore, oral estrogen administration indirectly 
stimulates GH secretion by restraining the central feedback inhibition of IGF-1 (Figure 1A). 
Oral estrogen delivery but not transdermal delivery also attenuates whole body fat oxidation 
and protein anabolism in women with hypopituitarism during GH therapy [39]. Furthermore, 
oral estrogen increases the concentration of IGFBP-1 [40], reducing the bioactivity of an 
already reduced concentration of IGF-1, leading to a further loss of an anabolic effect. 
Collectively, estrogen exerts mechanistically distinct and site-specific effects on the GH 
system:  a paracrine action in central stimulation of GH secretion and an endocrine action in 
inhibiting hepatic GH action, resulting in secondary activation of  GH secretion. 
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2.4. Effect on the GH Receptor  
Strong evidence indicates that estrogens inhibit the function of the GH receptor. The JAK-
STAT pathway is a major effector of GHR signaling, necessary for the transcriptional 
regulation of IGF-1. Estrogen inhibits GH activation of the JAK/STAT pathway. The 
inhibition is dose-dependent and suppresses GH-induced JAK2 phosphorylation and 
downstream transcriptional activity [41]. The termination of GHR signaling is controlled by 
the suppressors of cytokine signaling (SOCS) proteins and by protein tyrosine phosphatases. 
Estrogen does not affect phosphatase activity but stimulates hepatic expression of SOCS-2, 
which in turn inhibits JAK2 activation [41]. Therefore, estrogen suppresses GH receptor 
signaling by stimulating SOCS-2 expression, which in turn inhibits JAK2 phosphorylation, 
explaining the inhibitory effect of GH action on the liver. 
 
Estrogens affect the expression and function of GHRs in a tissue specific manner. 
Gonadotropic and somatotropic axes exert overlapping roles in regulating bone growth in 
men and women [42]. Contrary to the hepatic effect, estradiol stimulates GH signaling by 
reducing SOCS-2 expression in osteoblasts [43]. Estrogen amplifies GH-induced STAT-5 
phosphorylation in osteoblasts, increasing GH-induced bone-sialoprotein, osteopontin and 
IGF-2 mRNA expression [43]. GH co-treatment with estrogen synergistically induce 
osteoblast proliferation [44]. Therefore, estrogen potentiates the effect of GH on bone 
formation at least partly through the reduction of SOCS-2 negative feedback, which 
stimulates GH-responsive gene expression in bone. 
      
In summary, local estrogen derived from aromatization stimulates GH secretion in men and 
women. Estrogen exerts tissue-specific effect on GH signaling, inhibiting hepatic GH action 
resulting in a reduction of IGF-1 production. In bone, estrogen potentiates GH signaling 
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promoting bone formation. 
 
3. Estrogen compounds and GH 
Therapeutic compounds that modulate estrogen action or its availability affect the GH-IGF-1 
system. Estrogen compounds fall into two important therapeutic classes: selective estrogen 
receptor modulators (SERMs) and aromatase inhibitors. 
 
3.1. SERMs 
SERMs are synthetic estrogen compounds that exert agonist or antagonistic action in a tissue- 
specific manner. They have emerged as therapeutic agents for infertility, osteoporosis and 
breast cancer. Examples of SERMs in therapeutic use are clomiphene, tamoxifen and 
raloxifene. Tamoxifen exerts central estrogen receptor antagonistic but peripheral agonistic 
effect on the liver [45, 46]. As discussed above, estrogen drives GH secretion, a paracrine 
action that is unmasked by tamoxifen which blocks estrogen action and reduces GH secretion. 
Acting as estrogen agonist on the liver,  tamoxifen reduces hepatic IGF-1 production via a first-
pass effect [36, 37]. Despite the fall in feedback inhibition by IGF-1, GH secretion is not 
enhanced but rather reduced by tamoxifen, a manifestation of its powerful estrogen receptor 
antagonistic effect centrally [36]. SERMs, therefore, exert a double negative effect on the GH-
IGF-1 axis, inhibiting GH secretion centrally and GH action peripherally in the liver, 
collectively inducing a state of GH deficiency (Figure 1B).  
 
3.2. Aromatase Inhibitors  
Aromatase inhibitors are used increasingly for breast cancer therapy. Exemestrane, 
anastrozole and letrozole are aromatase inhibitors approved for clinical use. Inhibition of 
aromatase activity predictably reduce GH secretion [47]. Central effect of aromatase 
inhibitors is expected to be similar to that of tamoxifen, as these drugs reduce local estrogen 
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availability. Because aromatase is not expressed in the adult liver [48, 49], aromatase 
inhibitors do not affect the hepatic action of GH. Therefore, its pharmacodynamics effect on 
the GH system is purely central but less than that of SERMs, which exert dual central and 
peripheral effects. 
Estrogens, SERMs and aromatase inhibitors, therefore, all affect GH secretion and IGF-1, in 
different ways and degrees. These effects are presented in Table 1. 
 
3.3. Gender Differences  
The effect of SERMs and aromatase inhibitors on the GH axis is different between men and 
women [37]. This is because, in men, SERMs concurrently stimulate the pituitary-gonadal axis, 
increasing testosterone production, which mitigates suppression of the GH system. Like the GH 
system, estrogen regulates gonadotrophin secretion via a paracrine mechanism. Unlike the GH 
system, local estrogen derived from aromatization inhibits gonadotrophin secretion [50]. We 
reported that central estrogen blockade with SERMs enhanced LH secretion, consequently 
increasing testosterone levels [37, 51]. The higher testosterone levels in turn result in secondary 
stimulation of GH secretion. As this mitigating effect does not occur in women, the inhibitory 
effect of SERMs on GH secretion is greater in women than in men [37]. For a similar reason, 
the suppression of fat oxidation by tamoxifen is also greater in women but not in men [52].  
      
In summary, both SERMs and aromatase inhibitors suppress GH secretion. The effect of 
SERMs on the GH system is mitigated by concurrent stimulation of the gonadal system in men.  
This results in suppression of the GH system and of fat metabolism that are gender-dependent 
with effects that are greater in women than in men. 
 
4. Testosterone and GH 
4.1 GH Secretion 
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Testosterone exerts anabolic effect in part by stimulating the GH-IGF-1 system [53-57]. In 
men with hypogonadism, testosterone replacement stimulates GH secretion that drives IGF-1 
production [58]. Importantly, non-aromatizable androgens do not stimulate GH secretion 
[59], whereas aromatase inhibitor or central estrogen antagonism attenuates the stimulation of 
GH secretion by testosterone [47, 58]. These findings provide unequivocal evidence that local 
estrogens play a pivotal role in the regulation of GH secretion in men. Therefore, testosterone 
in men requires conversion to estradiol to stimulate GH secretion. 
4.2. GH action 
With regard to mechanisms mediating testosterone-modulation of GH action, there is 
evidence that testosterone modifies GHRs in the liver and in extrahepatic tissues. 
Testosterone increases the expression of GHR mRNA in the liver and in growth plates of 
castrated rabbits [60]. A similar effect occurs in the growth plates of hypophysectomized rats 
[61]. Testosterone, therefore, modulates the peripheral action of GH on the growth plate and 
liver by enhancing GHR expression. 
 
Human studies show that testosterone augments the biological effects of GH. In children with 
hypopituitarism, stimulation of growth by GH is augmented by co-treatment with testosterone 
[62]. In men with hypopituitarism, testosterone augments the stimulation of fat oxidation and 
protein synthesis [57, 63], and muscle IGF-1 gene expression [64, 65] induced by GH.  GH 
itself increases androgen receptor gene expression in muscle of hypogonadal men [66]. These 
observations provide strong evidence that androgens increase tissue responsiveness to GH, in 
part by enhancing GHR abundance.  
4.3 Protein Metabolism 
Human studies from our laboratory show strong interactions between testosterone and GH in 
regulating whole body protein anabolism. In hypopituitary men, GH and testosterone 
independently stimulate protein synthesis, with the effect being additive when co-treated [57]. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
Testosterone replacement induced a protein anabolic effect only in the presence of GH [67]. 
Both hormones are required to optimize protein anabolism and the interaction occurs in the 
liver. In men with hypogonadism with sufficient GH, oral administration of a low dose of 
testosterone  that exposes only the liver to testosterone enhanced whole body protein 
anabolism [67]. This effect is equivalent to that of systemic testosterone administration by the 
transdermal route. This interesting finding indicates that the liver rather than peripheral 
tissues is the site where GH and testosterone positively interact in enhancing whole body 
protein anabolism. We replicated this finding in post-menopausal women in whom 
administration of low-dose oral testosterone also stimulated whole-body protein anabolism 
[68]. We also observed that oral testosterone administration increased circulating IGF-1 
levels [67, 68]. These observations indicate that the liver is the primary site where 
testosterone and GH interact in regulating whole body protein anabolism.  
4.4 Physical effects 
The anabolic effects of GH on physical performance are potentiated by androgens. In a study 
of recreational athletes, combined administration of GH and testosterone increased the 
functional component of muscle mass, the body cell mass [14]. Testosterone also augmented 
other aspects of GH action, such as collagen tissue synthesis. GH increases collagen synthesis 
in skeletal muscle and tendon [69], and the stimulatory effect of GH on circulating markers of 
collagen synthesis is potentiated by testosterone [70]. GH administration stimulated sprint 
capacity when administered alone, and the effect was potentiated when combined with 
testosterone [14]. These findings indicate that both GH and testosterone interact in enhancing 
anabolism and muscle function.  
 
In summary, testosterone stimulates GH secretion through aromatization to estradiol and 
directly enhances GHR function. The liver is a primary site where testosterone and GH 
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interact to regulate protein metabolism. Both GH and testosterone are required to exert full 
anabolic effects. 
 
5. Clinical practice implications 
The regulatory interactions of the GH system by sex steroids have practical and clinically 
relevant information for women and men with hypopituitarism. The information should guide 
clinical practice in the therapeutic use of sex steroids and related compounds in women with 
hypopituitarism who are GH deficient. 
5.1 Women 
Women with hypopituitarism of reproductive age usually receive estrogen replacement 
therapy until they reach menopausal years, usually around the age of 50 years. In clinical 
practice, such women are rarely replaced with estrogens beyond the age of 50 years. Although 
rare, some women with hypopituitarism may not be able to tolerate estrogen therapy and may 
be considered for treatment with SERMs if osteoporosis co-exists. 
5.1.1. Estrogen replacement 
Because estrogen antagonizes the metabolic actions of GH on the liver, estrogen should be 
replaced by a non-oral route of administration in women with hypopituitarism. For women 
with hypopituitarism with GH deficiency and not replaced with GH, oral estrogen 
administration will worsen the GH deficient state. For those taking GH replacement, oral 
estrogen replacement reduces the therapeutic benefit of GH.  
   
Unfortunately, parenteral estrogen replacement is not widely practised. In a single centre 
survey, among GH deficient women receiving concurrent estrogen therapy, only 19% 
received estrogen via a transdermal route [71]. IGF-1 levels were lower in those taking 
ethinyl estradiol despite this group receiving a much higher dose of GH. The study also 
estimated that oral estrogen therapy substantially increases the annual cost of GH therapy 
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[71]. From the Pfizer KIMS database, among 315 women with hypopituitarism taking 
estrogens, 86% were prescribed oral formulations, with one-third using oral contraceptive 
steroids [72]. On average, those taking oral contraceptives required 55–70% more GH, and 
those taking oral formulations 20–30% more than those using transdermal patches [71, 72]. 
The GH sensitivity index, expressed as a change in IGF-1 over GH dose, is least for ethinyl 
estradiol, followed by estradiol valerate, and highest with transdermal estrogen replacement 
[73]. Therefore, the route and type of estrogen therapy determine the cost and benefits of GH 
replacement in GH deficient women. 
5.1.2. Effects of SERMs 
SERMs may be used in the management of women with hypopituitarism who are intolerant of 
estrogen therapy, eg. from menorrhagia or irregular bleeding. 
     
The effects of SERM on the GH and gonadal axes are dependent on the dose and the type. In 
studies comparing tamoxifen and raloxifene, we observed tamoxifen to be more potent in 
suppressing the GH axis in the doses used.  A dose of 20 mg tamoxifen significantly reduced 
circulating IGF-1 concentration, an effect greater than that from a 120 mg dose of raloxifene 
[37]. Therefore, tamoxifen in the doses used is more potent than raloxifene in inhibiting the GH 
axis.  
 
The effects of raloxifene on IGF-1, substrate metabolism and body composition in 
hypopituitary during GH therapy have been compared with 17ß-estradiol. During GH therapy, 
the increase in IGF-1 is reduced equally by raloxifene or 17ß-estradiol; however, raloxifene 
mitigates the beneficial effects of GH on fat mass, lean body mass and bone mineral density to 
a greater degree than 17ß-estradiol [74, 75]. As raloxifene but not estradiol increase the 
principle IGF-1 binding protein IGFBP-3, a fall in IGF-1 bioactivity may explain reduced 
anabolism observed with raloxifene treatment [74]. However, the raloxifene effects on 
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bioactive IGF-1 are similar to that of estrogen, highlighting that other mechanisms to IGF-1 
mediation are involved [76]. Therefore, raloxifene offers no advantage over oral estrogen to 
GH-deficient women during GH replacement and may well be detrimental. 
 
GH plays a major role in the regulation of hepatic lipid metabolism, as revealed by a 
prevalence of fatty liver of up to 77% of patients with GH deficiency [77]. As GH stimulates 
hepatic triglyceride export and fatty acid oxidation, the inhibitory effect on hepatic GH action 
by SERMS may lead to suppress hepatic lipid metabolism resulting in liver steatosis 
development [52, 74, 78, 79]. Fatty liver development is a risk of tamoxfen therapy in women 
with breast cancer [80]. In contrast to SERMs, fatty liver is not an adverse effect of aromatase 
inhibitors as they do not affect hepatic GH action.  
  
This inhibitory effect of SERMs on hepatic GH action has been exploited recently as a 
treatment option for acromegaly. Tamoxifen treatment up to 40 mg daily reduced circulating 
IGF-1 levels in 80% and normalized IGF-1 in almost 50% patients with acromegaly [81]. 
Although tamoxifen should be used with caution in patients with GH deficiency as GH 
replacement dose adjustments may be required, in acromegaly, tamoxifen might prove to be an 
effective adjuvant therapy. 
  
In summary, the prevalence of oral estrogen use in women with hypopituitarism is very high. 
The treatment of estrogen deficiency by oral formulations in women with hypopituitarism 
cannot be recommended, as it substantially reduces GH effectiveness, increasing GH 
replacement cost. When contraceptive instead of replacement doses of estrogen are 
prescribed, the waste of GH is even greater.  SERMs in therapeutic doses induce similar if not 
greater antagonism of GH action and their use in women with hypopituitarism is to be 
avoided. 
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5.2. Men 
Testosterone and GH exert similar effects on body composition and physical function; they 
also act together in augmenting each other’s effects. In men with hypopituitarism, 
concomitant GH and testosterone replacement is needed to achieve optimal effects on protein 
anabolism, body composition and muscle function. The adverse effects of GH and 
testosterone, however, are more frequent when co-administered [14, 82]. This is important 
information when initiating GH and testosterone replacement, in minimizing side-effects such 
as edema, myalgia and arthralgia. For this reason, stepwise introduction of GH and 
testosterone replacements along with gradual dose adjustments is advised.   
 
6. Summary and conclusion 
In summary, sex steroids regulate the secretion and action of GH through a mix of paracrine 
and endocrine mechanisms. In both men and women, local estrogens derived from the 
aromatization of androgens stimulate GH secretion. Estrogens and androgens exert distinct 
and opposite endocrine-mediated effects on hepatic IGF-1 production, protein and lipid 
metabolism. Drugs that inhibit central local estrogen production or action reduce GH 
secretion, whereas oral estrogen formulations and estrogen agonists antagonize GH action on 
the liver. Androgens enhance the secretion and action of GH. 
 
In conclusion, sex steroids substantially influence substrate metabolism and body 
composition through paracrine and endocrine modulation of the GH-IGF axis. Drugs that 
mimic or block estrogen action or estrogen availability are widely used as therapeutic 
substances, and have the potential of impairing metabolic health. The therapeutic benefit of 
GH in women with hypopituitarism is unaffected when estrogens are replaced by a non-oral 
route. Testosterone maximizes the metabolic and anabolic benefits of GH. 
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Practice Points. 
• In women with hypopituitarism, contraceptive formulations of estrogens are to be 
avoided and estrogen should be replaced by a non-oral route of administration. 
• SERMs offer no metabolic advantage over estrogens in women with hypopituitarism. 
• In men with hypopituitarism, androgens can be replaced by an oral or non-oral route 
of administration. 
• In patients with hypopituitarism replaced with sex steroids, women require a larger 
replacement dose of GH than men. 
 
Research agenda 
• The metabolic consequences of SERMs in men and women should be investigated. 
• Regular auditing of appropriate prescriptive use of estrogens in women with 
hypopituitarism should be undertaken. 
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Table 1. Effects of sex steroids and estrogen compounds on GH secretion and circulating 
IGF-1 levels 
 
 Effect on GH Effect on IGF-1 
Oral estrogen   
SERMs   
Aromatase inhibitors   
Testosterone   
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Figure legends 
Figure 1: A: Estrogen administered via oral route acts on the liver to reduce IGF-1 
production through first pass hepatic effect. The reduction in IGF-1 lessens negative feedback 
to the hypothalamus and pituitary gland and GH secretion is stimulated. B: Tamoxifen 
treatment also reduces IGF-1 levels, however due to central estrogen receptor antagonism by 
tamoxifen, GH secretion is attenuated. Studies indicate an important role of locally produced 
estrogen from testosterone through aromatization in the neuroregulation of GH secretion. 
(Adopted from [36]). 
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